MYC and plasma cell myeloma: Such treatments have already been attempted with IRES inhibitors; normal interactions with RBPs are blocked, decreasing the rate of c-Myc translation and consequently reducing tumor survival in multiple myeloma, breast, and colorectal cancer models (Vaklavas et al. 2015; Wiegering et al. 2015; Shi et al. 2016).